Literature DB >> 2011929

Use of vincristine in refractory thrombotic thrombocytopenic purpura.

M Levin1, H W Grünwald.   

Abstract

We describe 3 patients with thrombotic thrombocytopenic purpura (TTP) treated with vincristine. In 2 of them, multimodality treatment with plasmapheresis, acetylsalicylic acid, dipyridamole, corticosteroids, and plasma infusions did not achieve lasting remission, subsequent to which the administration of vincristine was followed by prompt and durable remission. In the third patient, 1 mg of intravenous vincristine as initial therapy in conjunction with multimodality treatment resulted in the prompt resolution of the disease. Our experience suggests that vincristine is effective in the treatment of TTP and can be used as initial treatment in combination with other modalities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2011929     DOI: 10.1159/000204850

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

Review 1.  The thrombocytopenic purpuras. Recognition and management.

Authors:  S Gillis
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

2.  Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange.

Authors:  A Pereira; R Mazzara; J Monteagudo; C Sanz; L Puig; A Martínez; A Ordinas; R Castillo
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

3.  Thrombotic microangiopathy in haematopoietic cell transplantation: an update.

Authors:  Evi Stavrou; Hillard M Lazarus
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-11-03       Impact factor: 2.576

4.  Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Authors:  Seniz Öngören; Ayşe Salihoğlu; Tuğçe Apaydın; Sevil Sadri; Ahmet Emre Eşkazan; Muhlis Cem Ar; Tuğrul Elverdi; Zafer Başlar; Yıldız Aydın; Teoman Soysal
Journal:  Balkan Med J       Date:  2018-07-03       Impact factor: 2.021

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.